Company intelligence / Profile preview

KAHR Therapeutics

Modi'in Makabim-Re'ut, Israel

Ownership: Private
Development stage: Other

Overview

KAHR’s lead program DSP107, a bispecific, bifunctional fusion protein combining SIRPα and 4-1BBL, has completed a Phase 1/2a trial in third-line microsatellite-stable colorectal cancer with reported improvements in survival, response rate, and disease control rate, and the company is seeking funding for a randomized Phase 2b trial in colorectal cancer.[1][2]

Therapeutic areas: Oncology
Modalities: Recombinant fusion proteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on KAHR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAHR Therapeutics.

Explore the full profile